TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Join Dr. Tiffany Traina for data from the pivotal TROPION-Breast02 trial and find out what these findings could mean for your clinical practice.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
